ProCE Banner Activity

Iberdomide Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase Ib/IIa Dose Escalation Study

Slideset Download
Conference Coverage
Iberdomide, a novel IMiD, was well tolerated and active in heavily pretreated patients with R/R MM.

Released: June 07, 2019

Expiration: June 05, 2020

Share

Provided by

Provided by the USF Health
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Astellas Seattle Genetics

Bayer Healthcare Pharma

Blueprint Medicines

Celgene

Novartis Pharmaceuticals Corporation

Puma Biotechnology, Inc.

Taiho Oncology Inc

Tesaro